Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Calcitonin Gene Related Peptide (CGRP) - Overview
Calcitonin Gene Related Peptide (CGRP) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Calcitonin Gene Related Peptide (CGRP) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Calcitonin Gene Related Peptide (CGRP) - Companies Involved in Therapeutics Development
AfaSci Inc
Aptarion Biotech AG
Eli Lilly and Co
H. Lundbeck AS
Kissei Pharmaceutical Co Ltd
Nepsone ehf
Pharmnovo AB
Serometrix LLC
Teva Pharmaceutical Industries Ltd
Vaxxinity Inc
Calcitonin Gene Related Peptide (CGRP) - Drug Profiles
AFAP-3 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
eptinezumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
fremanezumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
galcanezumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy to Inhibit CGRP for Medullary Thyroid Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KCZ-1279 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NOXL-41 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit CGRP for Migraine and Osteoarthritis Pain - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit CGRP for Pain - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit CGRP for Psoriasis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
UB-313 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Calcitonin Gene Related Peptide (CGRP) - Dormant Products
Calcitonin Gene Related Peptide (CGRP) - Discontinued Products
Calcitonin Gene Related Peptide (CGRP) - Product Development Milestones
Featured News & Press Releases
Jun 23, 2021: Teva announces Ministry of Health, Labour and Welfare approves AJOVY (fremanezumab) Injection in Japan for the preventive treatment of Migraine in Adults
Jun 21, 2021: New data supporting the safety and efficacy profile of AJOVY (fremanezumab) shared at 7th European Academy of Neurology Congress
Jun 16, 2021: Lilly plans head-to-head study of Emgality to prevent migraine
Jun 16, 2021: Lilly plans head-to-head study of Emgality to prevent migraine
Jun 15, 2021: The Jourl of the American Medical Association publishes data on efficacy and safety of preventive migraine treatment VYEPTI (eptinezumab-jjmr) when administered during an active migraine attack
Jun 03, 2021: Teva to present latest data on AJOVY (fremanezumab-vfrm) Injection at the 2021 American Headache Society (AHS) Annual Meeting, showcasing Teva’s longstanding heritage in the magement of Migraine
Jun 03, 2021: Lilly reveals real-world evidence data of Emgality at AHS 2021
Jun 03, 2021: New Clinical and Real-World Data evaluating efficacy of AJOVY (fremanezumab-vfrm) Injection presented at 2021 American Headache Society (AHS) Annual Meeting
Jun 03, 2021: Lundbeck to showcase new VYEPTI (eptinezumab-jjmr) data at 63rd Annual Scientific Meeting of the American Headache Society (AHS)
Apr 19, 2021: New data presented at 2021 American Academy of Neurology (AAN) Annual Meeting Shows VYEPTI (eptinezumab-jjmr) demonstrated earlier time to freedom from headache pain and absence of most bothersome symptoms compared to placebo
Apr 19, 2021: New clinical and real-world data evaluating efficacy of AJOVY (fremanezumab-vfrm) injection and reduction of migraine burden presented at 2021 American Academy of Neurology Virtual Annual Meeting
Apr 15, 2021: Teva to present new alyses of AJOVY (fremanezumab-vfrm) Injection at Upcoming 2021 American Academy of Neurology Virtual Annual Meeting, highlighting Teva’s ongoing commitment to neurology
Apr 08, 2021: Teva Cada announces new autoinjector for AJOVY for the preventive treatment of migraine in adults
Feb 26, 2021: New study published in Cephalalgia identifies mechanistic differences among CGRP migraine treatments
Feb 25, 2021: Emgality (galcanezumab) now approved for use in Cada for the treatment of episodic cluster headache
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures

List of Figures
Number of Products under Development by Stage of Development, 2021
Number of Products under Development by Therapy Areas, 2021
Number of Products under Development by Top 10 Indications, 2021
Number of Products by Stage and Mechanism of Actions, 2021
Number of Products by Routes of Administration, 2021
Number of Products by Stage and Routes of Administration, 2021
Number of Products by Molecule Types, 2021
Number of Products by Stage and Molecule Types, 2021

List of Tables

List of Tables
Number of Products under Development by Stage of Development, 2021
Number of Products under Development by Therapy Areas, 2021
Number of Products under Development by Indication, 2021
Number of Products under Development by Companies, 2021
Products under Development by Companies, 2021
Products under Development by Companies, 2021 (Contd..1)
Number of Products under Investigation by Universities/Institutes, 2021
Products under Investigation by Universities/Institutes, 2021
Number of Products by Stage and Mechanism of Actions, 2021
Number of Products by Stage and Route of Administration, 2021
Number of Products by Stage and Molecule Type, 2021
Pipeline by AfaSci Inc, 2021
Pipeline by Aptarion Biotech AG, 2021
Pipeline by Eli Lilly and Co, 2021
Pipeline by H. Lundbeck AS, 2021
Pipeline by Kissei Pharmaceutical Co Ltd, 2021
Pipeline by Nepsone ehf, 2021
Pipeline by Pharmnovo AB, 2021
Pipeline by Serometrix LLC, 2021
Pipeline by Teva Pharmaceutical Industries Ltd, 2021
Pipeline by Vaxxinity Inc, 2021
Dormant Projects, 2021
Discontinued Products, 2021